[HTML][HTML] Evaluation of immune-related response criteria and RECIST v1. 1 in patients with advanced melanoma treated with pembrolizumab
FS Hodi, WJ Hwu, R Kefford, JS Weber… - Journal of Clinical …, 2016 - ncbi.nlm.nih.gov
Journal of Clinical Oncology, 2016•ncbi.nlm.nih.gov
Purpose We evaluated atypical response patterns and the relationship between overall
survival and best overall response measured per immune-related response criteria (irRC)
and Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1. 1) in patients
with advanced melanoma treated with pembrolizumab in the phase Ib KEYNOTE-001 study
(clinical trial information:
survival and best overall response measured per immune-related response criteria (irRC)
and Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1. 1) in patients
with advanced melanoma treated with pembrolizumab in the phase Ib KEYNOTE-001 study
(clinical trial information:
Abstract
Purpose
We evaluated atypical response patterns and the relationship between overall survival and best overall response measured per immune-related response criteria (irRC) and Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1. 1) in patients with advanced melanoma treated with pembrolizumab in the phase Ib KEYNOTE-001 study (clinical trial information:
ncbi.nlm.nih.gov